Lundbeck VP joins board of migraine firm

Rehaler, which is developing a medical device to treat migraine episodes, has expanded its board with the addition of Bjørn Krogh Sperling, who is also spearheading Lundbeck’s migraine and pain research.

Photo: Rehaler / PR

Rehaler, a migraine firm developing a medical device of the same name to treat migraine episodes, has expanded its board of directors with a Lundbeck leader, Bjørn Krogh Sperling, according to a filing on the Danish Central Business Register.

Joining Lundbeck in 2018, Krogh Sperling currently holds the title of Vice President Clinical Research, Head of Dept. of Migraine & Pain at the firm. He has also previously spent a number of years at US-based Biogen, and before then he worked at the sclerosis department at Hillerød Hospital.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs